Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
Status:
Terminated
Trial end date:
2020-12-21
Target enrollment:
Participant gender:
Summary
The purpose of the protocol is to determine safety, tolerability, recommended dose (RD),
pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of IPN60090
as a single agent (Part A) and in combination with pembrolizumab (Part B) or paclitaxel (Part
C) in patients with advanced solid tumours and to evaluate food effect (Part D).